The US Food and Drug Administration’s negative review for Intercept Pharmaceuticals’s obeticholic acid has set off questions about the fate of other non-alcoholic steatohepatitis (NASH) drug hopefuls.
Among them is Zydus Lifesciences Limited, the sole Indian company evaluating a New Chemical Entity saroglitazar
During a call to discuss earnings in Q4 of FY23, which ended 31 March, the company’s CEO Sharvil Patel said Zydus has received approval to conduct studies for NASH from the regulatory authorities of Turkey, the